<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04356326</url>
  </required_header>
  <id_info>
    <org_study_id>CHASAP</org_study_id>
    <secondary_id>2018-004160-58</secondary_id>
    <nct_id>NCT04356326</nct_id>
  </id_info>
  <brief_title>Chronic Hypertension and Acetyl Salicylic Acid in Pregnancy</brief_title>
  <acronym>CHASAP</acronym>
  <official_title>Chronic Hypertension and Acetyl Salicylic Acid in Pregnancy, a Multicenter Prospective Randomized Double-blind Placebo-controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Intercommunal Creteil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Intercommunal Creteil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized clinical trial to assess the efficiency of acetylsalicylic acid (aspirin) 150&#xD;
      mg/day started before 15 weeks of gestation in the prevention on maternal and fœtal&#xD;
      complications in pregnant women with chronic hypertension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic hypertension affects 1 to 5% of women of childbearing age. According to the&#xD;
      literature, about 45% of pregnant women with chronic hypertension will develop complications&#xD;
      such as superimposed preeclampsia (PE), placental abruption, Intra Uterine Growth Restriction&#xD;
      (IUGR), perinatal death, maternal death, or preterm delivery. To date, there is no curative&#xD;
      treatment of vascular complications of chronic hypertension during pregnancy. The only&#xD;
      effective treatment, once the complications are established, is usually stopping the&#xD;
      pregnancy and delivering the placenta. The preventive treatment of these complications is&#xD;
      therefore an important axis in the improvement of maternal and perinatal health.&#xD;
&#xD;
      Due to the very high risk of superimposed PE in chronic hypertensive patients and despite the&#xD;
      lack of objective evidence of the effectiveness of low-dose aspirin in the prevention of&#xD;
      superimposed PE in this population, the NICE (National Institute for Health and Care&#xD;
      Excellence), associated with the Royal College of Gynecology-Obstetrics, recommends since&#xD;
      2010-2011 the use of low-dose aspirin in the prevention of this complication in chronic&#xD;
      hypertensive pregnant women; then it was followed by the &quot;U.S. Preventive Services Task Force&#xD;
      (USPTF)&quot; in 2014. Recently, the American College of Obstetrics and Gynecology (ACOG) adopted&#xD;
      the suggestions of the USPTF and issued the same recommendations in 2018. The French college&#xD;
      of obstetric (CNGOF: National College of French Gynecologists and Obstetricians), however,&#xD;
      does not recommend the use of low-dose aspirin in pregnant chronic hypertensive women because&#xD;
      of insufficient data.&#xD;
&#xD;
      Indeed, although the efficacy of low-dose aspirin is assumed in patients with previous PE,&#xD;
      few studies have evaluated its efficacy in patients with chronic hypertension. Moreover, most&#xD;
      of the controlled prospective studies using very low doses of aspirin (less than 100 mg) and&#xD;
      starting after 15 weeks of gestation do not seem conclusive. For these reasons, the&#xD;
      investigators propose to conduct a prospective randomized double-blind placebo-controlled&#xD;
      trial to analyze the effectiveness of aspirin dosed at 150 mg and introduced before 15 weeks&#xD;
      of gestation in women with chronic hypertension.&#xD;
&#xD;
      The primary endpoint is a maternal and perinatal composite morbidity and mortality including&#xD;
      superimposed PE, intrauterine growth restriction, preterm delivery &lt; 37 weeks of gestation,&#xD;
      placental abruption, perinatal death, or maternal death.&#xD;
&#xD;
      The definition of superimposed PE in our study is the appearance of significant proteinuria&#xD;
      in a chronic hypertensive pregnant woman.&#xD;
&#xD;
      In a secondary analyze, the statistician will use the new definition of superimposed PE that&#xD;
      does not require the mandatory presence of proteinuria but the association of chronic&#xD;
      hypertension and the appearance of neurological signs (eclampsia, persistent headache, visual&#xD;
      disturbances, severe nausea or vomiting), pulmonary edema, persistent epigastric pain,&#xD;
      thrombocytopenia &lt;100000 platelets/µL, liver enzymes at 2 times normal, renal insufficiency (&#xD;
      serum creatinine ≥ 97 μmol/L or 1.1 mg/dL,) or a doubling of serum creatinine in the absence&#xD;
      of chronic renal disease or significant proteinuria after 20 weeks of gestation or&#xD;
      postpartum.&#xD;
&#xD;
      Significant proteinuria is defined as greater than 300 mg/24 hours or when the ratio&#xD;
      proteinuria/ creatininuria is ≥ 30 mg/mmol (ratio to 0.3 if all are in mg/dL), in a&#xD;
      non-proteinuric women with no urinary tract infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2021</start_date>
  <completion_date type="Anticipated">October 2028</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective multicentric randomized double-blind superiority trial, placebo-controlled, on two parallel arms</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The treatment will be administered double blind. Pouches or tablets and caskets will be indistinguishable, prepared in advance and made available to pharmacies in participating hospitals by the sponsor. The treatment boxes are given as the monthly visits to the patient, a reassignment box will be required on the server at each visit to obtain a new cabinet number. The cabinet number (detachable label) used at each visit will be reported in the patient's file.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Composite morbidity-mortality criterion including preeclampsia, intra-uterine growth retardation &lt;10th percentile, placental abruption, Preterm birth &lt; 37 weeks of gestation, Perinatal death, Maternal death</measure>
    <time_frame>9 months</time_frame>
    <description>A composite morbidity-mortality criterion that includes the occurrence during pregnancy or postpartum of at least one of the following events: preeclampsia, IUGR &lt;10th percentile, placental abruption, Preterm birth &lt; 37 weeks of gestation, Perinatal death (death from 22 weeks of gestation until 28 days after birth), Maternal death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IUGR (&lt; 10th percentile of birth weight)</measure>
    <time_frame>9 months</time_frame>
    <description>Rate of IUGR (&lt; 10th percentile of birth weight)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placental abruption</measure>
    <time_frame>9 months</time_frame>
    <description>Rate of placental abruption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm birth &lt; 37 weeks of gestation</measure>
    <time_frame>9 months</time_frame>
    <description>Rate of severe preterm delivery (&lt; 37 weeks of gestation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal death</measure>
    <time_frame>9 months</time_frame>
    <description>Rate of severe maternal death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe pre-eclampsia</measure>
    <time_frame>9 months</time_frame>
    <description>Rate of severe pre-eclampsia. Concerning the rate of superimposed PE, it will be analyze according the two definition specified in the rational</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intrauterine growth restriction (IUGR)</measure>
    <time_frame>9 months</time_frame>
    <description>Rate of severe IUGR (&lt; 5th percentile of birth weight)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm delivery</measure>
    <time_frame>8 months</time_frame>
    <description>Rate of severe preterm delivery (&lt; 34 weeks of gestation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal loss</measure>
    <time_frame>5 months</time_frame>
    <description>Rate of fetal loss (fetal loss between 10 and 21 weeks of gestation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal death</measure>
    <time_frame>5 months</time_frame>
    <description>Rate of fetal death (fetal death from 22 weeks of gestation until delivery)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal death</measure>
    <time_frame>9 months</time_frame>
    <description>Rate of neonatal death (death from birth until 28 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal morbidity</measure>
    <time_frame>9 months</time_frame>
    <description>Neonatal morbidity (stay in a neonatal intensive care unit, assisted ventilation &gt; 24 hours, hyaline membrane disease, intraventricular hemorrhages stage III or IV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of aspirin</measure>
    <time_frame>8 months</time_frame>
    <description>Potential toxicity of the treatment: major maternal bleeding event (active externalized, intracranial, intra-ocular, retroperitoneal, articular), or minor,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence</measure>
    <time_frame>8 months</time_frame>
    <description>Adherence of treatment (diary) and its relationship with the efficacy of the preventive effect on primary outcome,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological response to the treatment</measure>
    <time_frame>4 months</time_frame>
    <description>Response to the treatment by a urine thromboxane assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiogenic profile</measure>
    <time_frame>9 months</time_frame>
    <description>Circulating and urinary angiogenic profile associated with maternal and fetal clinical data: sFLT1 ( Soluble fms-like tyrosine kinase-1)(serum and urine), PlGF ( Placental Growth Factor)(serum and urine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child development</measure>
    <time_frame>2 years</time_frame>
    <description>Child psychomotor development and health problems at 2 years of age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child development</measure>
    <time_frame>4 years</time_frame>
    <description>Child psychomotor development and health problems at 4 years of age</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Chronic Hypertension Complicating Pregnancy</condition>
  <condition>Pre-Eclampsia</condition>
  <condition>Intrauterine Growth Restriction</condition>
  <condition>Aspirin</condition>
  <condition>Perinatal Death</condition>
  <condition>Placental Abruption</condition>
  <arm_group>
    <arm_group_label>Aspirin 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin 150 mg / day (acetylsalicylic acid) once daily in the evening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo taken in the evening</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 150 mg</intervention_name>
    <description>Treatment assigned by randomization will be prescribed immediately and continued throughout pregnancy up to 35 weeks + 6 days for both groups. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the evening. A daily log is given to patients and must be completed every day.</description>
    <arm_group_label>Aspirin 150 mg</arm_group_label>
    <other_name>Active arm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Treatment assigned by randomization will be prescribed immediately and continued throughout pregnancy up to 35 weeks + 6 days for both groups. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the evening. A daily log is given to patients and must be completed every day.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>comparator arm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant patient between 10 and 14 weeks of gestation + 6 days&#xD;
&#xD;
          -  Chronic hypertension, whether treated or not, know before pregnancy or diagnosed&#xD;
             before randomization&#xD;
&#xD;
          -  Singleton pregnancy&#xD;
&#xD;
          -  Signed the written informed consent&#xD;
&#xD;
          -  Affiliation to social security&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ---Medical history requiring anticoagulation (antiphospholipid syndrome, deep vein&#xD;
             thromboembolic disease, pulmonary embolism, atherothrombosis, patient with mechanical&#xD;
             heart valves),&#xD;
&#xD;
          -  Patient receiving aspirin for another indication outside pregnancy,&#xD;
&#xD;
          -  Patient with significant proteinuria (&gt; 300mg/24 hours or a proteinuria/creatininuria&#xD;
             ratio ≥ 30mg/mmol),&#xD;
&#xD;
          -  Active bleeding,&#xD;
&#xD;
          -  History of severe PE with delivery &lt; 34 weeks of gestation,&#xD;
&#xD;
          -  Hypersensitivity to salicylates such as aspirin and other nonsteroidal&#xD;
             anti-inflammatory drugs (NSAIDs),&#xD;
&#xD;
          -  Platelet count lower than 100,000 cells/microliter (dosage less than 6 months old),&#xD;
&#xD;
          -  Hemostasis disorders, including hemophilia (with thrombocytopenia)&#xD;
&#xD;
          -  Any constitutional or acquired hemorrhagic disease, (including digestive hemorrhages,&#xD;
             history of hemorrhagic stroke and thrombocytopenia&#xD;
&#xD;
          -  Human immunodeficiency virus, or hepatitis B virus, or hepatitis C virus positive&#xD;
             serum,&#xD;
&#xD;
          -  Patient included in an another interventional study,&#xD;
&#xD;
          -  Age &lt;18 years old,&#xD;
&#xD;
          -  Women under the protection of justice,&#xD;
&#xD;
          -  Patients with psychiatric follow-up, poor understanding of French or cognitive&#xD;
             problems,&#xD;
&#xD;
          -  Duodenal ulcer,&#xD;
&#xD;
          -  Severe renal impairment,&#xD;
&#xD;
          -  Severe hepatic insufficiency,&#xD;
&#xD;
          -  Severe cardiac impairment,&#xD;
&#xD;
          -  Gout,&#xD;
&#xD;
          -  Patients with known glucose-6-phosphate dehydrogenase deficiency,&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bassam HADDAD</last_name>
    <phone>01 45 17 55 43</phone>
    <phone_ext>+33</phone_ext>
    <email>bassam.haddad@chicreteil.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Camille JUNG</last_name>
    <phone>01 45 17 50 00</phone>
    <phone_ext>+33</phone_ext>
    <email>camille.jung@chicreteil.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loïc SENTILHES</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patricia DOLLEY</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Antoine Béclère, AP-HP</name>
      <address>
        <city>Clamart</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra BENACHI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Louis Mourier, AP-HP</name>
      <address>
        <city>Colombes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanne SIBIUDE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Créteil</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bassam HADDAD, Ph</last_name>
      <phone>0145175543</phone>
      <phone_ext>+33</phone_ext>
      <email>bassam.haddad@chicreteil.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Bicêtre, AP-HP</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie -Victoire SENAT</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Muriel DORET-DION</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital St Joseph</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raoul DESBRIERE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier MOREL</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norbert WINER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Cochin- Port Royal, AP-HP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vassilis TSATSARIS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Robert Débré, AP-HP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane KORB</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Trousseau, AP-HP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre DELORME</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Poissy</name>
      <address>
        <city>Poissy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick ROZENBERG</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU St Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiphaine BARJAT</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck PERROTIN</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 19, 2020</study_first_submitted>
  <study_first_submitted_qc>April 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Fetal Growth Retardation</mesh_term>
    <mesh_term>Pregnancy Complications</mesh_term>
    <mesh_term>Abruptio Placentae</mesh_term>
    <mesh_term>Perinatal Death</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

